Context Therapeutics (CNTX) Projected to Post Earnings on Wednesday

Context Therapeutics (NASDAQ:CNTX) will likely be posting its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.10) per share for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. On average, analysts expect Context Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Context Therapeutics Stock Performance

Shares of CNTX opened at $0.60 on Tuesday. The stock has a 50-day moving average price of $1.04 and a 200 day moving average price of $1.94. The company has a market capitalization of $55.50 million, a P/E ratio of -1.44 and a beta of 1.74. Context Therapeutics has a one year low of $0.55 and a one year high of $3.62.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new stake in Context Therapeutics in the 4th quarter valued at approximately $3,824,000. Marshall Wace LLP boosted its position in Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after acquiring an additional 2,557,448 shares during the period. Vanguard Group Inc. grew its stake in shares of Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Context Therapeutics by 858.8% in the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after purchasing an additional 91,008 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Context Therapeutics by 8.5% during the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after purchasing an additional 13,000 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CNTX has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Friday, July 17th. Maxim Group cut their target price on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Finally, Wall Street Zen cut shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $6.17.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.